Auron Therapeutics, Inc.

"You can have the best drug in the world, but if you don't know how to use it, it's not gonna help you." In Part 2 of The Biotech Startups Podcast conversation with Auron Therapeutics, Inc. Founder & CEO Kate Yen, a central theme revolves around marrying deep biological insight with clinical execution to maximize therapeutic impact. – From lab bench to bedside: Kate’s journey leading Agios’ IDH inhibitor program, where biomarker development and mechanistic studies became the backbone of clinical trial design – Avoiding the "over-the-wall" trap: Why translational biology must run parallel to drug discovery from day 1 to inform physician use cases – Clinical trial optimization: Partnering with regulators early and using biomarker-driven patient stratification to reduce costs while improving outcomes – Platforms with purpose: How Auron’s differentiation-focused approach and developmental biology atlas aim to rewrite cancer treatment paradigms – Resourceful company-building: Launching a lean biotech through strategic CRO partnerships and shared lab spaces while keeping science front-and-center This episode crackles with hard-won insights about bridging discovery and clinical impact – including how Kate’s team achieved FDA approvals using phase 1 data. Head over to Apple Podcasts or Spotify for this episode and more stories only a biotech exec can tell! #biotechnology #lifesciences #podcast

We're excited to share that we've received Fast Track Designation in AML! https://lnkd.in/e-JYPBdP

Check out Part 1 of our CEO @Kate Yen’s conversation on The Biotech Startups Podcast. Dive into Kate’s insights into the power of collaboration in biotech, her journey from academia to industry, and how embracing diverse perspectives drives innovation in drug development. Listen to the full episode on Apple Podcasts or Spotify! #biotechnology #lifesciences #drugdevelopment

Excited to announce FDA clearance of our IND application for AUTX-703, our first-in-class oral KAT2A/B degrader, and the completion of our $27M Series B financing! We’re advancing AUTX-703 into clinical development for hematological malignancies in Q1 2025, while expanding our KAT2A/B program into autoimmune indications. Read the full announcement: https://lnkd.in/e982WsNG #Biotechnology #Oncology #DrugDevelopment #SeriesB

In the most recent instalment of #ScripAsks2025, our CEO and founder Kate Yen shared her predictions for the role #AI will play in the #biopharma industry in 2025. Our AI-powered platform, AURIGIN?, enables us to efficiently discover and develop next-generation targeted cancer therapies. Get the full insights from Kate: https://bit.ly/4jGkJWO

Auron is hiring! We are looking for a full-time or consulting Medical Director to support our phase 1 trials. https://lnkd.in/eau-gXrG

Today, we proudly presented preclinical data for our lead program at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition in San Diego, CA. This development highlights the dose-dependent survival advantage of AUTX-703 in a patient-derived AML model. These findings validate the strength of our AURIGIN? platform, which combines AI and machine learning to identify innovative oncology targets. With IND submissions on track before year-end and plans to move into the clinic in 2025, we’re excited to bring next-generation cancer therapies closer to reality. ?? Read the full press release here: https://lnkd.in/eFgXfNtC #ASH

We're very excited to be presenting pre-clinical data on AUTX-703 at the American Society of Hematology (ASH) Annual Meeting. #ASH #Leukemia

The Auron team is excited to be presenting at the EORTC-NCI-AACR (ENA) Symposium and Prostate Cancer Foundation (PCF) Annual Scientific Retreat this week #ENASymp2024 #PCF

Thrilled to have presented data at #ACSFall2024, highlighting the strength of @AuronTherapeutics' #medicinalchemistry capabilities in #cancer drug discovery and development. Our team is leveraging deep expertise to advance a pipeline of next-generation #targetedtherapies to help transform #oncology treatment in the future.